Long-term metabolic changes with bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir-containing regimens for HIV
No significant difference in weight change from baseline to Week 144 was found between bictegravir and DTG, or between B/F/TAF and a non-TAF-containing regimen, in these two randomized trials. Furthermore, weight gain following treatment initiation was greatest in the first year of treatment and most pronounced in individuals with more advanced HIV at baseline, supporting the hypothesis that weight gain following initial treatment is linked to a "return to health" in people with advanced HIV.
Authors
- Paul E. Sax (ORCID: https://orcid.org/0000-0001-8434-174X)
- Chloe Orkin (ORCID: https://orcid.org/0000-0001-6168-6745)
- Juan Tiraboschi (ORCID: https://orcid.org/0000-0002-0073-873X)
- Anton Pozniak (ORCID: https://orcid.org/0000-0002-4091-5323)
- Moti N. Ramgopal (ORCID: https://orcid.org/0000-0001-7448-1976)
- Sharline Madera (ORCID: https://orcid.org/0000-0003-3658-5488)
- Eric S. Daar (ORCID: https://orcid.org/0000-0003-1880-7331)
- Kimberly Workowski (ORCID: https://orcid.org/0000-0002-9918-9493)
- Jason T. Hindman (ORCID: https://orcid.org/0000-0003-1513-3423)
- Hui Liu (ORCID: https://orcid.org/0009-0002-1407-0117)
- Chris Deaton
- Cal Cohen
- Cynthia Brinson
- Debbie Hagins (ORCID: https://orcid.org/0000-0001-7478-7609)
Institutions
- Brigham and Women's Hospital (US)
- Emory University (US)
- Midway University (US)
- Queen Mary University of London (GB)
- UCLA Medical Center (US)
- Bellvitge University Hospital (ES)
- London School of Hygiene & Tropical Medicine (GB)
- Gilead Sciences (Spain) (ES)
- Coastal Health District (US)
- Chelsea and Westminster Hospital (GB)
- Gilead Sciences (United States) (US)
- Harbor–UCLA Medical Center (US)
Publication Details
- Journal
- AIDS Research and Therapy
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1186/s12981-025-00732-w
- Citations
- 3
- Primary Topic
- HIV-related health complications and treatments
- Type
- article
- Field-Weighted Citation Impact
- 6.76
Funders
- Gilead Sciences
- University of Warwick